NCT00915083 2019-11-01A Phase I Study to Assess the Safety, Pharmacokinetics, and Potential Effects of Amrubicin on the QT/QTc Interval in Cancer Patients With Advanced Solid Tumors.CelgenePhase 1 Completed24 enrolled